Trial Profile
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 26-Week Multicenter Study to Evaluate the Efficacy and Safety of Ertugliflozin in Asian Subjects With Type 2 Diabetes Mellitus and Inadequate Glycemic Control on Metformin Monotherapy (VERTIS-ASIA)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 14 Feb 2023
Price :
$35
*
At a glance
- Drugs Ertugliflozin (Primary) ; Glimepiride; Metformin
- Indications Obesity; Overweight; Type 2 diabetes mellitus
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms VERTIS; VERTIS-Asia
- Sponsors Merck Sharp & Dohme
- 03 Feb 2023 Results of pooled post hoc analysis from two studies(n=445; NCT02033889 and NCT02630706) assessing the efficacy and safety of ertugliflozin in participants from Asia with T2D and baseline BMI 24 kg/m(2), with inadequate glycemic control on metformin published in the Diabetes Therapy
- 05 Oct 2018 Primary endpoint (Change from Baseline in HbA1c at Week 26) has been met, according to the results presented at the 54th Annual Meeting of the European Association for the Study of Diabetes
- 05 Oct 2018 Results presented at the 54th Annual Meeting of the European Association for the Study of Diabetes